TY - JOUR
T1 - Single-dose safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, in HIV-infected children
AU - Yogev, Ram
AU - Kovacs, Andrea
AU - Chadwick, Ellen G.
AU - Homans, James D.
AU - Lou, Yu
AU - Symonds, William T.
PY - 2005/1
Y1 - 2005/1
N2 - A phase I, open-label, dose-escalating trial was conducted to evaluate the safety, tolerability, and pharmacokinetics of single, oral doses of amprenavir (141W94), a potent inhibitor of human immunodeficiency virus type 1 (HIV-1) protease, in 20 HIV-infected children 4 to 12 years of age. The doses of amprenavir evaluated, 5, 10, 15, and 20 mg/kg of body weight, were comparable to those evaluated in adult phase I and II studies. The most common clinical adverse event associated with amprenavir, administered as soft gelatin capsules, was nausea. Amprenavir was rapidly absorbed, with a mean time to maximum concentration (Tmax) occurring 0.95 to 1.58 h after dosing. The area under the concentration-time curve (AUC0→∞) was dose proportional, and the mean maximum plasma concentration (Cmax) increased linearly in a less than dose-proportional manner. Amprenavir was eliminated relatively slowly, with a mean terminal-phase half-life (t 1/2) of 6.17 to 8.28 h. The t1/2, apparent total clearance, and apparent volume of distribution during the elimination phase were dose independent. Considerable interpatient variability was seen for all pharmacokinetic parameters of amprenavir. The results of this study suggest that 20 mg of amprenavir/kg administered twice a day should be used in future pediatric studies.
AB - A phase I, open-label, dose-escalating trial was conducted to evaluate the safety, tolerability, and pharmacokinetics of single, oral doses of amprenavir (141W94), a potent inhibitor of human immunodeficiency virus type 1 (HIV-1) protease, in 20 HIV-infected children 4 to 12 years of age. The doses of amprenavir evaluated, 5, 10, 15, and 20 mg/kg of body weight, were comparable to those evaluated in adult phase I and II studies. The most common clinical adverse event associated with amprenavir, administered as soft gelatin capsules, was nausea. Amprenavir was rapidly absorbed, with a mean time to maximum concentration (Tmax) occurring 0.95 to 1.58 h after dosing. The area under the concentration-time curve (AUC0→∞) was dose proportional, and the mean maximum plasma concentration (Cmax) increased linearly in a less than dose-proportional manner. Amprenavir was eliminated relatively slowly, with a mean terminal-phase half-life (t 1/2) of 6.17 to 8.28 h. The t1/2, apparent total clearance, and apparent volume of distribution during the elimination phase were dose independent. Considerable interpatient variability was seen for all pharmacokinetic parameters of amprenavir. The results of this study suggest that 20 mg of amprenavir/kg administered twice a day should be used in future pediatric studies.
UR - http://www.scopus.com/inward/record.url?scp=11244261647&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=11244261647&partnerID=8YFLogxK
U2 - 10.1128/AAC.49.1.336-341.2005
DO - 10.1128/AAC.49.1.336-341.2005
M3 - Article
C2 - 15616313
AN - SCOPUS:11244261647
SN - 0066-4804
VL - 49
SP - 336
EP - 341
JO - Antimicrobial agents and chemotherapy
JF - Antimicrobial agents and chemotherapy
IS - 1
ER -